

14 December 2006

To All Pharmaceutical Suppliers, Hospital Pharmacists, Medical Groups and Interested Parties

**Consultation on a provisional agreement with Pacific Pharmaceuticals for the listing of quetiapine (Quetapel) on the Pharmaceutical Schedule**

PHARMAC and Pacific Pharmaceuticals Limited have entered into a provisional agreement to list quetiapine (Quetapel) in Sections B and H of the Pharmaceutical Schedule as soon as is practicable following Medsafe registration (but not before 1 July 2007). We are now seeking feedback on this proposal.

Key aspects of this proposal are as follows:

- Quetiapine (Quetapel) would be listed in Section B and in Part II of Section H of the Pharmaceutical Schedule at the following prices and subsidies (ex-manufacturer, excluding GST):

Pharmaceutical	Brand	Form	Strength	Pack Size	Price and subsidy
Quetiapine	Quetapel	Tablet	25 mg	90	\$20.62
Quetiapine	Quetapel	Tablet	100 mg	90	\$41.25
Quetiapine	Quetapel	Tablet	200 mg	90	\$70.88
Quetiapine	Quetapel	Tablet	300 mg	90	\$119.25

- Quetapel would be fully subsidised without the requirement for endorsement for subsidy that currently applies to the Seroquel (AstraZeneca) brand of quetiapine in Section B of the Pharmaceutical Schedule.
- Quetapel would have protection from delisting and subsidy reduction until 1 December 2009.

If you wish to make comments for the PHARMAC Board to consider when making its decision on whether to accept this proposal, please forward them to PHARMAC by **5:00 pm, 12 January 2007**. All comments submitted by this date will be considered.

Yours sincerely



Geraldine MacGibbon  
Therapeutic Group Manager

P5-3-7 #105864

*Investing in Health*